Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

PHASE4CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
HIVHepatitis CCirrhosis
Interventions
DRUG

Harvoni

Treatment of Hepatitis C with sofosbuvir based HCC therapy

Trial Locations (8)

10029

Mt. Sinai Medical Center, New York

10032

Columbia University, New York

19104

University of Pennsylvania, Philadelphia

20057

Georgetown University, Washington D.C.

20892

National Institutes of Health Clinical Center, Bethesda

21201

University of Maryland, Baltimore

21287

Johns Hopkins Medical Center, Baltimore

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

Columbia University

OTHER

collaborator

University of Pennsylvania

OTHER

collaborator

University of Maryland, College Park

OTHER

collaborator

Georgetown University

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

National Institutes of Health Clinical Center (CC)

NIH

lead

University of California, San Francisco

OTHER

NCT02533934 - Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant | Biotech Hunter | Biotech Hunter